European Commission approves Amgen’s cancer drug Kyprolis in combo therapy
November 20, 2015Research and Development, Sales and Marketing
The European Commission (EC) has today granted marketing authorization for Amgen’s Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone for …
Bioproject’s narcolepsy treatment recommended for European approval
November 20, 2015Research and Development, Sales and Marketing
The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Bioproject’s Wakix (pitolisant) for the treatment of narcolepsy …
Biogen’s Enbrel biosimilar gets positive CHMP opinion
November 20, 2015Research and Development, Sales and Marketing
The Committee for Medicinal Products for Human Use (CHMP) today gave a positive opinion to Benepali- the first biosimilar version …
Turing boss Shkreli joins KaloBios as CEO; takes 70% of shares
November 20, 2015Medical Communications, Research and Development
KaloBios Pharmaceuticals has announced the appointment of Turing CEO Martin Shkreli as its own new CEO and his election as …
Alan Dunton appointed senior vice president at Purdue Pharma
November 20, 2015Manufacturing and Production, Medical Communications, Research and Development
Purdue Pharma LP has announced the appointment of Alan Dunton, MD, to the role of senior vice president of Research …
Lilly and Merck extend immuno-oncology collaboration
November 20, 2015Medical Communications, Research and Development Eli Lilly, Merck
Eli Lilly and Merck have announced the extension of their existing collaboration to evaluate the safety and efficacy of the …
Bayer awaits FDA decision on new contraceptive
November 20, 2015Medical Communications, Research and Development
Bayer has submitted a new drug application (NDA) to the FDA, seeking approval for LCS-16, an investigational hormonal intrauterine device …
PMCPA rules on two Bayer conduct breach allegations
November 20, 2015Medical Communications, Sales and Marketing
The pharma industry regulator in the UK, the PMCPA, has ruled on two alleged breaches of the ABPI code of …
Top five pharma controversies of 2015 (so far)
November 20, 2015Medical Communications, Sales and Marketing AstraZeneca, Martin Shkreli, Philidore, Takeda, Turing Pharmaceutical, Valeant, Warner Chilcott, controversies, fraud, reputation, tax avoidance, turing
5. AstraZeneca forced to deny tax avoidance allegations
New partner drives Simon-Kucher’s Life Sciences growth in the UK
November 19, 2015Medical Communications
The global strategy and marketing consultancy Simon-Kucher & Partners has appointed eleven new partners for 2016, with eight of them …
American Medical Association calls for ban on drug commercials
November 19, 2015Medical Communications, Sales and Marketing
The American Medical Association (AMA) has called for a ban on the promotion of prescription products; action which it believes …
NHS England and NICE announce plans for new Cancer Drugs Fund
November 19, 2015Medical Communications, Research and Development Cancer Drugs Fund, NHS England, NICE
A 12-week consultation on draft proposals for a revamped Cancer Drugs Fund (CDF) has been launched by NHS England and NICE, …
Physicians Interactive becomes Aptus Health, offering a global digital health engagement solution
November 19, 2015Medical Communications
Physicians Interactive has announced that it has become Aptus Health, reflecting its mission of advancing health engagement and its role …
NICE decision restricts Bayer’s Xofigo to select prostate cancer patients
November 19, 2015Research and Development, Sales and Marketing Bayer, NICE, prostate cancer
NICE has issued its Final Appraisal Determination (FAD) recommending Bayer’s Xofigo (radium-223 dichloride) for use on the NHS in England …
FDA grants Merck and Pfizer priority review for PD-L1 cell treatment
November 19, 2015The FDA has granted Merck and Pfizer’s avelumab Breakthrough Therapy Designation for the treatment of patients with metastatic merkel cell …
Merck criticises NICE ‘no’ to personalised bowel cancer drugs
November 19, 2015Research and Development
NICE has issued preliminary not recommending two specific personalised treatments used in combination with chemotherapy for previously untreated metastatic colorectal …
Merck KGaA completes $17bn Sigma-Aldrich acquisition
November 18, 2015Manufacturing and Production, Sales and Marketing M&A Sigma Aldridge, Merck, acquisitions, mergers
Merck KGaA has announced the completion of its $17 billion acquisition of Sigma-Aldrich, having cleared the final regulatory hurdle and …
Obama FDA commissioner nominee Califf defends big pharma ties
November 18, 2015Sales and Marketing Bernie Sanders, FDA, FDA commissioner, Robert Califf
President Obama’s nominee to head the FDA was forced to defend his history of ties to the pharma industry as …
Raising Awareness: World COPD Day
November 18, 2015Medical Communications COPD, COPD disease, COPD exacerbation, Synergy Vision, disease awareness, medical communications
World COPD Day 18th November 2015
NICE rejects Amgen’s Repatha in draft guidance
November 18, 2015Research and Development, Sales and Marketing Amgen, NICE, Repatha, evolocumab, high cholesterol
NICE has published draft guidance rejecting Amgen’s Repatha as a treatment for people with high cholesterol.
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales
